What do you make of the Azixa 2a trial design (disclosed at JMP) Hobden is saying that the patient response to azixa is not linear and that (based on the one complete response) the disease may tend to show some progression after 6 month, when in reality what comes up in the MRI is inflammation around the shrinking tumor?
This is old news. They're harping on it to make sure the analysts with room temperature IQs understand why the criteria for judging response are going to be different going forward.
While they aren't doing drug discovery anymore, they have apparently kept some sharp drug biochemistry types. The unusual pharmacokinetics of Azixa suggest that a test analogous to OnDose could improve clinical results. I hope someone is working on that.